Jeffrey Strich
@JeffreyStrichMD
Followers
301
Following
267
Media
5
Statuses
94
Lasker Clinical Research Scholar National Heart Lung and Blood Institute Critical Care and Infectious Disease Physician Studying Sepsis Views are my own
Joined April 2020
Congratulations to Dr. Jeffrey Strich who was recently selected as a Lasker Scholar. Dr. Strich and his team at the NIH Clinical Center’s Critical Care Department are trying to find new ways to help people with life-threatening infections. https://t.co/KQeXtzGt3u
0
1
5
From developing treatments for life-threatening infections to improving early detection for skin cancer, the newest NIH Lasker Scholars are helping to enhance health outcomes. Learn more about the research advances made by Dr. Michael Sargen (left) and Dr. Jeffrey Strich
10
15
106
Sepsis is a leading cause of death. Take a look at our new work where we characterize low density neutrophils and identify spleen tyrosine kinase as a novel therapeutic target in our model of septic shock. https://t.co/i8YFjxlYUw
academic.oup.com
In a nonhuman primate model of bacterial sepsis, low-density neutrophils are elevated with increased heterogeneity over time and express high levels of spl
1
0
2
I am excited to share that I am starting my lab in NHLBI as a Lasker Clinical Research Scholar with the goal of understanding the pathogenesis and developing therapeutics for patients with infections that cause critical illness. @NIHCritCare @TheBethesdaLabs @Raquel_DaCruz
7
6
38
Check out our new manuscript evaluating the impact of R406 on LPS induced neutrophil activation. R406 can inhibit NETosis, ROS, and other end-effector functions of neutrophils that can be detrimental during sepsis! @TheBethesdaLabs @NIHCritCare
https://t.co/NYxIhNC0Hw
2
6
17
0
0
0
We (Laboratory of Critical Illness Pathogenesis and Therapeutics) are hiring for a post-doc position in the NHLBI Critical Care Medicine Branch. Great opportunity to investigate the role of myeloid cells in infections that cause critical illness. Link below to apply
1
3
4
Congratulations to Kiana Allen for her NIH Postbac presentation! She worked w/ Dr. Jeffrey Strich, M.D. in the NIH Clinical Center’s Critical Care Medicine Dept. Read her featured work : https://t.co/FQ2IHk7yEx. Learn more about the NIH Postbac Program: https://t.co/PkZNwhTwLf
0
2
9
@JeffreyStrichMD @chc_yek @morgan_walker4 @ManirajNeupane @AlexLawandi @Ahmed_HBabiker @CARB_X @koutterson @JohnRex_NewAbx @gardp_amr @AMRAlliance @ABsteward @reactgroup #AMR #idtwitter @IDSAInfo Also nice covering piece in Stat News by @edsilverman :
statnews.com
Newer antibiotics were underprescribed for hard-to-treat infections, a new study finds.
0
3
9
We (Pathogenesis and Therapeutics Section) are hiring a biologist in the NIH Critical Care Medicine Branch. Great opportunity to investigate the role of myeloid cells in infections that cause critical illness. Link to apply below.
0
4
13
IDSA and a coalition of medical professional societies have released recommendations for modifying the Centers for Medicare and Medicaid Services sepsis metrics to improve #sepsis care and outcomes. The recommendations: https://t.co/cgY4t6ieEJ Our press release:
0
11
16
🆕️⚡️⚡️Retrospective cohort 161 US hospitals @JeffreyStrichMD @AlexLawandi @SameerKadri12 Association between pip/tazo MIC & survival among hospitalized pts with Enterobacterales infections MIC of ≥32/4 mg/L is associated with increased mortality https://t.co/GAt5oeRFsI
1
24
71
I am happy to share our paper on the cellular immune response of vaccinated patients with SARS-CoV-2 breakthrough infections. Thanks to the COVID-ARC Team Group at NIH led by Dr. Anthony Suffredini! https://t.co/yPRFY90kMd
@atsearlycareer @NIHCritCare @nih_nhlbi @CCMedEd
4
7
43
3/3 Thanks to @NIHClinicalCntr @NIAIDNews @TheBethesdaLabs @NIH_NIAMS for the support on this exciting project.
1
0
3
2/3 We demonstrate that randomization to fostamatinib is associated with decreased neutrophil and monocyte activation using a variety of techniques including single-cell RNA-seq, high dimensional flow cytometry and soluble biomarkers.
1
0
5
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19 https://t.co/ab0fS5fSFX 1/3 Our new paper is out using samples from our phase II clinical trial evaluating fostamatinib in hospitalized patients with COVID-19.
science.org
Fostamatinib is associated with decreased neutrophil and monocyte activation in COVID-19.
2
4
15
Please Share! @CienciaPR @blakewarner0 @JeffreyStrichMD @YogenKanthi @wilfredo_nk @DavidKleiner12 @NIGMS @NIHClinicalCntr @NIAIDCareers
We are hiring a #postdoc to investigate molecular pathogenesis of emerging pathogens, including SARS-CoV-2! #postdocposition #postdocjobs #hiring #immunology #NIH #NIH_OITE #SHARONMILGRAM
0
3
3
Thank you @AnnalsofIM for showcasing our study on #COVID19 surges and mortality risk in their list of most influential articles of 2021: https://t.co/jXeRfycnHn
@NIHCritCare @NIHClinicalCntr @ASPRgov @sarahrenee314 @vineet_chopra
acpjournals.org
Background: Several U.S. hospitals had surges in COVID-19 caseload, but their effect on COVID-19 survival rates remains unclear, especially independent of temporal changes in survival. Objective: To...
From #BestofAnnals 2021 collection: Surges in #COVID19 caseload during the pandemic doubled mortality in the hardest-hit U.S. hospitals https://t.co/IOgpoP4Wi8. Study by @SameerKadri12 @sarahrenee314 et al. from @NIHClinicalCntr @NIHCritCare
0
2
10
Congratulations to two @nih leaders in infectious disease for their @IDSAInfo awards this evening. Well deserved. @LionakisLab
0
2
13
🌟Encouraging NIH data🌟 🆕💥💥 #CID @JeffreyStrichMD Phase 2 double-blind,placebo RCT Oral SYK inhibitor Fostamatinib for the treatment hospitalized adults requiring oxygen w #COVID19 Rigel Phase 3🔜 Fostamatinib 4th arm NIH ACTIV-4 host tissue NECTAR https://t.co/PyykV8xveZ
0
15
33